DK1011678T3 - Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders - Google Patents
Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disordersInfo
- Publication number
- DK1011678T3 DK1011678T3 DK98939328T DK98939328T DK1011678T3 DK 1011678 T3 DK1011678 T3 DK 1011678T3 DK 98939328 T DK98939328 T DK 98939328T DK 98939328 T DK98939328 T DK 98939328T DK 1011678 T3 DK1011678 T3 DK 1011678T3
- Authority
- DK
- Denmark
- Prior art keywords
- mecamylamine
- nicotine
- treatment
- neuropsychiatric disorders
- responsive
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 title 1
- 229960002525 mecamylamine Drugs 0.000 title 1
- 229960002715 nicotine Drugs 0.000 title 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5523497P | 1997-08-11 | 1997-08-11 | |
| US93536497A | 1997-09-22 | 1997-09-22 | |
| PCT/US1997/020689 WO1999007356A1 (en) | 1997-08-11 | 1997-11-07 | Nicotine antagonists for neuropsychiatric disorders |
| PCT/US1998/016634 WO1999007378A1 (en) | 1997-08-11 | 1998-08-11 | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1011678T3 true DK1011678T3 (en) | 2008-05-05 |
Family
ID=27368798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98939328T DK1011678T3 (en) | 1997-08-11 | 1998-08-11 | Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP4640888B2 (en) |
| AU (1) | AU8778498A (en) |
| CA (1) | CA2300148C (en) |
| DK (1) | DK1011678T3 (en) |
| ES (1) | ES2299214T3 (en) |
| WO (1) | WO1999007378A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2345767A1 (en) * | 1998-10-16 | 2000-04-27 | Paul Leonce Irma De Nijs | Therapy for improving cognition |
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| JP2007516275A (en) * | 2003-12-23 | 2007-06-21 | ファイザー・プロダクツ・インク | Therapeutic combinations for cognitive enhancement and psychotic disorders |
| CA2601509A1 (en) * | 2005-03-18 | 2006-09-28 | Abbott Laboratories | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions |
| US11766429B1 (en) | 2020-08-26 | 2023-09-26 | University Of South Florida | Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
-
1998
- 1998-08-11 JP JP2000506968A patent/JP4640888B2/en not_active Expired - Fee Related
- 1998-08-11 DK DK98939328T patent/DK1011678T3/en active
- 1998-08-11 ES ES98939328T patent/ES2299214T3/en not_active Expired - Lifetime
- 1998-08-11 WO PCT/US1998/016634 patent/WO1999007378A1/en not_active Ceased
- 1998-08-11 CA CA002300148A patent/CA2300148C/en not_active Expired - Fee Related
- 1998-08-11 AU AU87784/98A patent/AU8778498A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU8778498A (en) | 1999-03-01 |
| ES2299214T3 (en) | 2008-05-16 |
| CA2300148C (en) | 2009-06-23 |
| CA2300148A1 (en) | 1999-02-18 |
| JP2003524573A (en) | 2003-08-19 |
| WO1999007378A1 (en) | 1999-02-18 |
| JP4640888B2 (en) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1063990T3 (en) | Use of Biochanine-Enriched Extract for the Treatment of Estrogen-Associated Disorders | |
| DK1047428T3 (en) | Use of morpholinol in the treatment of sexual disorders | |
| IS5113A (en) | Use of CB1 antagonists for the treatment of craving disorders | |
| DK0830864T3 (en) | Combination therapy for the treatment of psychoses | |
| DK0812845T3 (en) | Process for the preparation of sildenafil | |
| DK0941103T3 (en) | Pharmaceutical preparation for the treatment of diabetes | |
| DK1028954T3 (en) | Substituted imidazoles suitable for the treatment of inflammatory diseases | |
| DK0966447T3 (en) | Useful small molecules for the treatment of inflammatory diseases | |
| DK0861081T3 (en) | Use of epinastine for the treatment of pain | |
| DK0937055T3 (en) | Process for the preparation of d, I-alpha-tocopherol | |
| DK0752870T3 (en) | Use of Mycobacterium for the treatment of tumors | |
| DK1053217T3 (en) | Process for the preparation of n-propanol | |
| DK199800837A (en) | Installations for the treatment of subjects | |
| DE69807225D1 (en) | Nonwoven TREATMENT | |
| DK1027315T3 (en) | Process for the preparation of n-butanol | |
| DE59707096D1 (en) | Hair treatment agent for setting the hair | |
| DK1028960T3 (en) | Process for the preparation of thiazolidinedione | |
| IT1303677B1 (en) | DEVICE FOR THE HEAT TREATMENT OF PIECES. | |
| DK0928183T3 (en) | Use of 1-hydroxy-2-pyridones for the treatment of seborrhoic dermatitis | |
| DK1011678T3 (en) | Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders | |
| DK0819113T3 (en) | Benzamides for the treatment of neurodegenerative disorders | |
| DK1012152T3 (en) | Process for the preparation of oxazaphosphorin-2-amines | |
| DK1200447T3 (en) | Oxazinocarbazoles for the treatment of CNS diseases | |
| DK0981349T3 (en) | 5-alpha-pregnan-3-beta-ol-20-one sulfate for the treatment of tumors and CNS diseases | |
| IS5481A (en) | Combination therapy for the treatment of AIDS |